The Firm recently represented the underwriters in connection with the public offering by Boston Scientific Corporation (“Boston Scientific”) of €900 million of its 0.625% Senior Notes due 2027. Boston Scientific used the net proceeds from the offering, together with cash on hand, to fund a related cash tender offer.
In addition, the Firm represented the dealer managers in connection with the related cash tender offer for up to $1 billion aggregate principal amount of Boston Scientific’s outstanding 4.125% Senior Notes due 2023, 4% Senior Notes due 2028, 3.85% Senior Notes due 2025 and 3.375% Senior Notes due 2022, settlement of which occurred concurrently with the completion of the notes offering.
Boston Scientific, as a global medical technology leader for 40 years, advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
The Simpson Thacher team for the transaction included Roxane Reardon, Clark Warthen, Camilla Johnson and Matt Drucker (Capital Markets); Jonathan Cantor and Ed Grais (Tax); Marcela Robledo and Alysha Sekhon (Intellectual Property); Michael Isby (Environmental); Jeanne Annarumma and Alyssa Ohanian (ECEB); and Jennie Getsin (FINRA/Blue Sky).